Thus identifying MLK3-dependent AP-1 target genes that are critical for cancer progression will not only provide a better understanding of how MLK3 signaling controls cancer invasion and metastasis, but also potentially lead to the development of predictive biomarkers which could be used to select cancer patients most likely to respond to treatments that block MLK3 function. This evidence concerns the gene JUN and cancer.